A new drug for rare soft-tissue cancers
Part of Cancer clinical trials.
This study tests a new drug called brenetafusp in people with rare soft-tissue cancers (synovial sarcoma or myxoid/round cell liposarcoma). The drug aims to help your immune system fight the cancer, and the study is checking if it is safe and works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have synovial sarcoma or myxoid/round cell liposarcoma that has spread or cannot be removed with surgery.
- You need to have a specific genetic marker called HLA-A*02:01, which can be checked with a blood test.
- You must have had at least one earlier cancer treatment, but no more than three for advanced disease.
- You should be 18 years or older and in reasonably good health (able to do most daily activities).
- Your blood counts and organ function need to be within certain ranges (checked before starting).
- If you have had brain metastases, they must have been treated and stable for at least 2 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a low dose of a common chemotherapy (liposomal doxorubicin) together with an anti-cancer drug called peposertib. It’s for people with advanced sarcoma that can’t be cured, aiming to find a safe dosing plan and see how well the treatment might work.
This trial tests a drug called N-803 for people with synovial sarcoma or myxoid/round cell liposarcoma that has gotten worse after T-cell therapy. N-803 may help the immune system fight the cancer, and the study will see if it can slow or stop the cancer from growing.
This Phase 1/2 study tests a new therapy for children and young adults with specific types of cancer that have been treated with chemotherapy before. It may help by targeting cancer features in the tumor and using your immune system in a controlled way.
This trial is testing whether a combination of two drugs—a targeted therapy (surufatinib) and an immunotherapy (envafolimab)—can help people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery. Researchers will also use a person's genetic information and scans to see if they can predict who will benefit the most.
This trial tests if a drug called tebentafusp can help people with advanced clear cell sarcoma that cannot be removed by surgery or has spread. It is for people with a specific immune marker (HLA-A*02:01) whose disease has gotten worse.
This trial tests a new immunotherapy drug (envafolimab) combined with two chemotherapy drugs (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior treatment. The goal is to see if this combination is safe and effective.
Hear when a new Metastatic Myxoid Liposarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.